Document is current

Any future updates will be listed below

Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective

Crossref DOI link: https://doi.org/10.1186/S12913-015-1139-Y

Published: 2015-06

Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY

About CrossMark